PulteGroup, Inc. (NYSE:PHM) reported stronger-than-expected results for the fourth quarter. The Atlanta, Georgia-based company posted a quarterly profit of $217.1 million, or $0.58 per share, versus a year-ago profit of $220.1 million, or $0.57 per share. According to the press release, the latest quarter included $0.16 per share of tax and insurance benefits, offset by $0.01 per share of lease exit costs. On Friday shares of PulteGroup, Inc. (NYSE:PHM) closed at $20.59. Company’s sales growth for last 5 years was -1.90% and EPS growth for next 5 years is recorded as 5.92%.
On January 15, Regado Biosciences, Inc. (NASDAQ:RGDO) announced that it has entered into a definitive merger agreement with privately-held Tobira Therapeutics, Inc. As per the agreement, Tobira will merge with a wholly-owned subsidiary of Regado in an all-stock transaction, and form a company focused on the development of novel treatments for liver and inflammatory diseases. Regado Biosciences, Inc. (NASDAQ:RGDO) in last trading activity advanced 8.85% to close at $1.23. Company weekly performance is 16.04% while its quarterly performance stands at 16.04%. Regado Biosciences, Inc. (NASDAQ:RGDO) is -91.28% away from its 52 week high.
VIVUS, Inc. (NASDAQ:VVUS) announced that the European Commission (EC) has adopted the commission implementing decision amending the marketing authorization for SPEDRA (avanafil). SPEDRA is now the first and only erectile dysfunction (ED) medication approved in Europe that is indicated to be taken as needed approximately 15 to 30 minutes before sexual activity. On last trading day VIVUS Inc. (NASDAQ:VVUS) fell -5.42% to close at $2.62. Its volatility for the week is 5.32% while volatility for the month is 6.39%. VVUS’s sales growth for past 5 years was -0.60% and its EPS growth for past 5 years was -65.30%. VIVUS Inc. (NASDAQ:VVUS) monthly performance is -5.76%.
TheStreet downgraded shares of Cresud S.A.C.I.F. y A. (NASDAQ:CRESY) from a hold rating to a sell rating in a report issued on Wednesday. Cresud S.A.C.I.F. y A. (ADR) (NASDAQ:CRESY) institutional ownership stands at 26.50%. In last trading activity company’s stock closed at $10.30.
Haemonetics Corporation (NYSE:HAE) reported third quarter fiscal 2015 revenue of $231.8 million, down 4.3%. In constant currency, revenue declined 1.4% in the quarter. The Company reported third quarter GAAP net income of $16.0 millionand GAAP net income per share of $0.31. On last trading day Haemonetics Corporation (NYSE:HAE) advanced 0.20% to close at $39.60. Its volatility for the week is 3.96% while volatility for the month is 2.92%. HAE’s sales growth for past 5 years was 9.40% and its EPS growth for past 5 years was -9.90%. Haemonetics Corporation (NYSE:HAE) monthly performance is 2.64%.